Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)

被引：7
|
作者：
Mamounas, Eleftherios P. [1 ,2 ]
Bandos, Hanna [3 ,4 ]
Lembersky, Barry C. [3 ,4 ]
Jeong, Jeon Hyeon [3 ,4 ]
Geyer, Charles E., Jr. [5 ,6 ]
Rastogi, Priya [3 ,4 ]
Fehrenbacher, Louis [7 ,8 ]
Graham, Mark L. [9 ,10 ]
Chia, Stephen K. [11 ,12 ]
Brufsky, Adam M. [3 ,13 ]
Walshe, Janice M. [14 ]
Soori, Gamini S. [15 ,16 ]
Dakhil, Shaker R. [17 ,18 ]
Seay, Thomas E. [19 ,20 ]
Wade, James L., III [21 ,22 ]
McCarron, Edward C. [23 ,24 ]
Paik, Soonmyung [25 ,26 ]
Swain, Sandra M. [27 ,28 ]
Wickerham, D. Lawerence [29 ]
Wolmark, Norman [3 ,4 ]
机构：
[1] NRG Oncol, Orlando, FL USA
[2] Orlando Hlth UF Hlth Canc Ctr, Orlando, FL USA
[3] NRG Oncol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] NRG Oncol, Richmond, VA USA
[6] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA USA
[7] NRG Oncol, Novato, CA USA
[8] Kaiser Permanente Oncol Clin Trials Northern, Novato, CA USA
[9] NRG Oncol, Cary, NC USA
[10] Waverly Hematol Oncol, Cary, NC USA
[11] NRG Oncol, Vancouver, BC, Canada
[12] British Columbia Canc Agcy, Vancouver, BC, Canada
[13] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
[14] Canc Trials Ireland, Dublin, Ireland
[15] NRG Oncol, Ft Myers, FL USA
[16] Florida Canc Specialists, Ft Myers, FL USA
[17] NRG Oncol, Wichita, KS USA
[18] CCOP Wichita Via Christi Reg Med Ctr, Wichita, KS USA
[19] NRG Oncol, Atlanta, GA USA
[20] Atlanta Canc Care, Atlanta, GA USA
[21] NRG Oncol, Decatur, IL USA
[22] Decatur Mem Hosp, Canc Care Specialists Illinois, Heartland NCORP, Decatur, IL USA
[23] NRG Oncol, Baltimore, MD USA
[24] Medstar Franklin Sq Med Ctr, Baltimore, MD USA
[25] NRG Oncol, Seoul, South Korea
[26] Yonsei Univ, Coll Med, Seoul, South Korea
[27] NRG Oncol, Washington, DC USA
[28] Georgetown Univ, Med Ctr, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[29] NSABP NRG Oncol, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-GS4-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS4-01
引用
收藏
页数：3
相关论文
共 16 条
  • [1] A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42
    Mamounas, E. P.
    Bandos, H.
    Lembersky, B. C.
    Geyer, C. E., Jr.
    Fehrenbacher, L.
    Graham, M. L.
    Chia, S. L.
    Brufsky, A. M.
    Hennessy, B. T.
    Soori, G. S.
    Dakil, S. R.
    Seay, T. E.
    Wade, J. L., III
    McCarron, E. C.
    Paik, S.
    Swain, S. M.
    Wickerham, D. L.
    Wolmark, N.
    CANCER RESEARCH, 2017, 77
  • [2] Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42
    Mamounas, E.
    Bandos, H.
    Lembersky, B.
    Geyer, C.
    Geyer, C., Jr.
    Fehrenbacher, L.
    Graham, M.
    Paik, S.
    Swain, S.
    Wickerham, L.
    Wolmark, N.
    BREAST, 2017, 32 : S25 - S26
  • [3] Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
    Mamounas, Eleftherios P.
    Bandos, Hanna
    Lembersky, Barry C.
    Jeong, Jong-Hyeon
    Geyer, Charles E., Jr.
    Rastogi, Priya
    Fehrenbacher, Louis
    Graham, Mark L.
    Chia, Stephen K.
    Brufsky, Adam M.
    Walshe, Janice M.
    Soori, Gamini S.
    Dakhil, Shaker R.
    Seay, Thomas E.
    Wade, James L., III
    McCarron, Edward C.
    Paik, Soonmyung
    Swain, Sandra M.
    Wickerham, D. Lawrence
    Wolmark, Norman
    LANCET ONCOLOGY, 2019, 20 (01): : 88 - 99
  • [4] Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
    Mamounas, Eleftherios P.
    Bandos, Hanna
    Rastogi, Priya
    Zhang, Yi
    Treuner, Kai
    Lucas, Peter C.
    Geyer, Charles E.
    Fehrenbacher, Louis
    Chia, Stephen K.
    Brufsky, Adam M.
    Walshe, Janice M.
    Soori, Gamini S.
    Dakhil, Shaker
    Paik, Soonmyung
    Swain, Sandra M.
    Sgroi, Dennis C.
    Schnabel, Catherine A.
    Wolmark, Norman
    CLINICAL CANCER RESEARCH, 2024, 30 (09) : 1984 - 1991
  • [5] Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 88, 2019)
    Mamounas, E. P.
    Bandos, H.
    Lembersky, B. C.
    LANCET ONCOLOGY, 2019, 20 (01): : E10 - E10
  • [6] Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer (vol 115, djad078, 2023)
    Mamounas, Eleftherios P.
    Bandos, Hanna
    Rastogi, Priya
    Lembersky, Barry C.
    Jeong, Jong-Hyeon
    Geyer, Charles E.
    Fehrenbacher, Louis
    Chia, Stephen K.
    Brufsky, Adam M.
    Walshe, Janice M.
    Soori, Gamini S.
    Dakhil, Shaker R.
    Wade, James L.
    McCarron, Edward C.
    Swain, Sandra M.
    Wolmark, Norman
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (11): : 1437 - 1437
  • [7] NSABP B-42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer
    Mamounas, Eleftherios P.
    Lembersky, Barry
    Jeong, Jong-Hyeon
    Cronin, Walter
    Harkins, Barbara
    Geyer, Charles
    Wickerham, Donald Lawrence
    Paik, Soonmyung
    Costantino, Joseph
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2006, 7 (05) : 416 - 421
  • [8] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
    Chia, Stephen
    Gradishar, William
    Mauriac, Louis
    Bines, Jose
    Amant, Frederic
    Federico, Miriam
    Fein, Luis
    Romieu, Gilles
    Buzdar, Aman
    Robertson, John F. R.
    Brufsky, Adam
    Possinger, Kurt
    Rennie, Pamela
    Sapunar, Francisco
    Lowe, Elizabeth
    Piccart, Martine
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1664 - 1670
  • [9] Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy plus /- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140).
    Chavez-Mac Gregor, Mariana
    Barlow, William E.
    Pusztai, Lajos
    Goetz, Matthew P.
    Rastogi, Priya
    Ganz, Patricia A.
    Mamounas, Eleftherios P.
    Paik, Soonmyung
    Bandos, Hanna
    Gralow, Julie
    Lew, Danika L.
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase Ill randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy plus /- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)
    Chavez-MacGregor, M.
    Barlow, W. E.
    Pusztai, L.
    Goetz, M. P.
    Rastogi, P.
    Ganz, P. A.
    Mamounas, E. P.
    Paik, S.
    Bandos, H.
    Gralow, J.
    Lew, D. L.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2016, 76
12